Abstract 79P
Background
The combination of chemotherapy and ICIs based on CPS cut-off >=5 is considered standard in advanced GCs. There is emerging data on the use of low dose (LD) ICIs in multiple cancers.
Methods
Data of patients with MSS advanced GCs receiving chemotherapy combined with ICIs between August 2021 and February 2024 was collated from eight institutions in India. The co-primary endpoints of the study were to identify the predictive value of a CPS cutoff >=5 [using Ventana SP263 or the Dako PD-L1 22C3 assay) being statistically significant in predicting for improved median OS and to compare median OS between patients receiving standard dose ICIs (SD-ICI) and LD-ICIs in patients with CPS >=5. Median OS was computed by Kaplan-Meier method.
Results
A total of 262 patients were available for analysis during the study period. The majority of patients received ICIs during second line therapy or beyond as opposed to first line therapy (148, 56% vs 114, 44%), with 201 patients (77%) receiving nivolumab (SD – 94, LD – 107) and 61 patients (23%) receiving pembrolizumab (SD-60; LD-1). With a median follow up of 12.5 months [95% Confidence interval (CI): 9.4-15.6], the median OS of the entire cohort was 14.4 months (95% CI: 10.3-18.6). The CPS cutoff >=5 (n=163) did not achieve statistical significance in predicting for improved OS compared to CPS<5 (n=99), during 1st line therapy (p=0.46) and or during later lines therapy (p=0.062). In patients with CPS>=5 (n=163), there was no significant differences in median OS in patients receiving LD-ICI (n=78) as compared to SD-ICI (n=85) (14.1 months vs. 16.1 months; p=0.95). No differences in OS were seen between the LD-ICI and SD-ICI cohorts, whether used initially or during later lines of therapy (p=0.988).
Conclusions
The use of a CPS cutoff >=5 for predicting outcomes in MSS advanced gastric adenocarcinomas probably needs to be standardized with respect to various platforms and re-visited for relevance in real world practice. Low dose immune checkpoint inhibitors can be evaluated in combination with chemotherapy in patients where standard dosing is not feasible due to logistics, pending evidence from prospective trials.
Legal entity responsible for the study
Tata Memorial Centre, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract